Best Grants for HIV / AIDS in Hawaii

The Ittleson Foundation, established in 1932, focuses on enhancing mental health, AIDS prevention, and environmental initiatives. It funds not-for-profit organizations aiming to improve public policy and the lives of citizens. The Foundation is particularly interested in innovative projects addressing mental health stigma, advancing preventative efforts, and supporting underserved populations. While it funds new initiatives, it does not typically support capital projects, endowments, or direct service programs outside New York City.

Students and recent graduates pursuing unpaid internships in HIV/AIDS research, advocacy, or services at U.S.-accredited institutions, including those in Hawaii, can receive funding to support their summer 2025 placements. Point Foundation supports LGBTQ+ and ally scholars through The Kadel & Gerhardt Internships, offering up to US $7,000 for academically talented candidates.

Research institutions and HIV/AIDS research centers in Hawaii and across the U.S. can seek funding to build and strengthen infrastructure for innovative HIV/AIDS research. With a mission to advance HIV science, the National Institutes of Health supports multidisciplinary collaborations, implementation science, and mentoring of early-career investigators through the Centers for AIDS Research network.

Research institutions and multidisciplinary scientific teams working on HIV and other infectious diseases in Hawaii can access funding through the National Institutes of Health to establish structural biology centers. These grants support high-resolution 3D structural analyses, computational molecular dynamics, and structure-guided design of molecules to develop new medicines, diagnostics, and prevention tools for priority infectious diseases.

Research institutions and other eligible organizations conducting substance use and HIV-related pilot studies in Hawaii can access funding through the National Institutes of Health. NIH provides U.S. HIV and substance use researchers with support to develop and test prevention, treatment, recovery, and implementation interventions, including feasibility studies, stakeholder engagement, and preparation for future large-scale trials.

Research institutions studying HIV/AIDS chronic conditions, coinfections, and comorbidities can pursue pioneering prevention or treatment projects through this NIH opportunity, including work relevant to Hawaii. The US Dept. of Health & Human Services National Institutes of Health supports early-career investigators, especially those focusing on pediatric and maternal populations and bringing innovative, cross-disciplinary approaches.

Research institutions studying HIV/AIDS and immunotherapy effects on the central nervous system can access funding via the National Institutes of Health for biphasic R21/R33 projects. This U.S. Dept. of Health & Human Services opportunity offers up to US $2,000,000 and may benefit Hawaii-based teams investigating CNS HIV persistence, neurotoxicity, and long-term neurologic outcomes.

Hawaii HIV/AIDS research institutions and clinical organizations can access funding through the National Institutes of Health to operate Clinical Trials Units supporting HIV and HIV-associated disease studies. These CTUs run randomized clinical trials and implementation research across domestic and international sites, contributing to efforts to end the HIV epidemic and improve prevention and treatment.

Research institutions with capacity for large-scale HIV clinical trials data management can apply for National Institutes of Health funding to lead Statistical and Data Management Centers supporting HIV prevention and treatment research, including work impacting Hawaii. With a mission to advance HIV/AIDS research, NIH supports SDMCs that design studies, manage data, and ensure regulatory compliance.

Research institutions and clinical laboratories working on HIV/AIDS prevention, treatment, and implementation research in Hawaii and other eligible U.S. locations can apply for laboratory center funding to support HIV clinical trials. US Dept. of Health & Human Services: National Institutes of Health provides support for up to four Laboratory Centers to manage testing, data systems, and advanced assays for Clinical Trials Networks.

Research institutions and clinical trial networks working on HIV/AIDS prevention, treatment, and implementation research in Hawaii can apply for National Institutes of Health support to lead a Clinical Trials Network Leadership and Operations Center. US Dept. of Health & Human Services: National Institutes of Health (NIH) funds LOCs focused on therapeutics, biomedical prevention, immune-based strategies, and maternal/adolescent/pediatric HIV care.

Public health agencies and research-focused organizations in Hawaii and other U.S. jurisdictions can apply for Centers for Disease Control and Prevention funding to conduct ongoing bio-behavioral surveillance among populations disproportionately affected by HIV. Support covers data collection on risk behaviors, HIV testing, prevention strategy use, and linkage to appropriate prevention or care services.

HIV and addiction research institutions in Hawaii can access funding through the National Institutes of Health to establish a NIDA Core Center of Transformative Science. Centers support interdisciplinary research on substance use, addiction, and HIV, providing shared resources, administrative support, and opportunities for early-career investigators while integrating and enhancing existing funded projects.

Research institutions and organizations conducting HIV/AIDS research in Hawaii and other eligible U.S. locations can apply for US Dept. of Health & Human Services: National Institutes of Health funding; awards US $212,004 - US $2,725,311 for integrated specific pathogen free in vivo model resources and human new approach methodologies to advance rigorous, translational HIV/AIDS studies.

Hawaii HIV / AIDS research institutions and collaborating organizations can access funding through the National Institutes of Health to establish or enhance NIMH HIV/AIDS Research Centers. This opportunity supports interdisciplinary mental health and HIV/AIDS research, fostering collaboration, innovation, and dissemination across basic, clinical, behavioral, social, translational, implementation science, and data science domains within eligible U.S. locations.

Health organizations and planning bodies working on HIV/AIDS prevention and care in Hawaii and other U.S. jurisdictions can seek funding to enhance integrated HIV services and planning. Grants from HRSA help strengthen Ryan White HIV/AIDS Program Part A and B recipients through tools, training, and technical assistance, with awards up to US $700,000.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.